Christophe Carité SVP, CMC & Process Development, 4D Pharma

Please introduce yourself and give a little background of your current activities?

Christophe is a French citizen graduated in industrial pharmacy (PharmD), Microbiology and Business Administration. He has joined 4D pharma at the early beginning of the company in 2014 and he has assumed the challenge to produce freeze dried strict anaerobic bacteria at the industrial scale level ( 3500 L fermentor, 5 to 20m2 Freeze dryer) to deliver high concentrated LBPs to patients (> 1010 CFU, shelf life up to 2years per capsules) recognised by several patent families granted. In addition, Christophe has integrated “in house” all 4D pharma Manufacturing and Controls under inspected cGMP.

Right now, he assume the position of Process development/CMC Senior Vice President and member of 4D Pharma Executive team reporting directly to the CEO.

What is the most exciting areas of gut microbiome you are currently working on?

Immuno-oncology, CNS.

What has been the most noticeable trends and exciting milestone that’s been achieved in microbiome in the past year?

Positive clinical datas on:

- C. diff,
- IBS,
- Immuno-oncology,

What do you think has been the driving force for these trends?

Right clinical study design.

What do you believe are the priorities for the gut microbiome community going into 2022?

Improvement of the existing clinical datas.

Where do you think the gut microbiome community should be focusing in light of these priorities?

To get the right IMP with right pharamaceutical form with the right viable cell count

Without giving too much away could you provide an introductory overview of what you will be looking to present (or address) at the upcoming Gut Microbiome Therapeutics Europe 2021? Why is this important to the audience?

Right now, the most important would be to think about the commercial products especially with Process Performance Qualification, in other words Process validation, Product shelf life.

What are you most looking forward to at Gut Microbiome Therapeutics Europe 2021?

Europe Regulatory position.